Primary Prevention Aspirin Eligibility Under a Contemporary Risk Framework - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Eligibility for Aspirin in Primary Prevention Using a Contemporary Cardiovascular Risk Framework

  • By

  • Sridhar Mangalesh

  • Sharanya Kaushik

  • Raiza Rossi

  • Armin Nouri

  • Shefa Arya Nezhad

  • Abdulla A. Damluji

  • Michael G. Nanna

  • November 19, 2026

Share

Clinical Scorecard: Eligibility for Aspirin in Primary Prevention Using a Contemporary Cardiovascular Risk Framework

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Eligibility for Aspirin in Primary Prevention Using a Contemporary Cardiovascular Risk Framework
Key MechanismsThe study compared aspirin eligibility estimates using PCE and base-model PREVENT-ASCVD risk estimates; PREVENT generally produces lower 10-year risk estimates than PCE.
Target PopulationUS adults aged 40 to 59 years without previous ASCVD who met the study’s exclusions for characteristics associated with major bleeding risk.
Care SettingCare setting described in the source article.

Key Highlights

  • The 2022 USPSTF recommendation calls for individualized decision-making about low-dose aspirin for adults aged 40 to 59 years with 10-year CVD risk of at least 10% and no increased bleeding risk.
  • In this cross-sectional analysis, estimated eligibility was 8.5% using PCE risk of at least 10%, compared with 10.4%, 3.4%, and 1.1% using PREVENT thresholds of at least 5%, 7.5%, and 10%, respectively.
  • Among aspirin nonusers, PREVENT at 5% produced eligibility estimates most comparable to PCE at 10%: 8.7% versus 7.4%.
  • Raising the PREVENT threshold progressively reduced eligibility and reclassified many PCE-eligible aspirin nonusers as ineligible.
  • The authors state that PREVENT-specific microsimulation studies evaluating thresholds between 5% and 10% are needed before recommendations can be formally revised.

Guideline-Based Recommendations

Diagnosis

  • The study estimated 10-year ASCVD risk using PCE and base-model PREVENT-ASCVD equations.

Management

    Monitoring & Follow-up

    • Not reported.

    Risks

      Patient & Prescribing Data

      NHANES 2013–2020 data for 4,289 US adults aged 40 to 59 years without previous ASCVD, representing an estimated 57.5 million adults; participants with specified bleeding-risk characteristics were excluded.

      Aspirin use was reported by 12.7% of participants. Among nonusers, estimated eligibility was 7.4% with PCE risk of at least 10%, and 8.7%, 3.7%, and 1.2% with PREVENT thresholds of at least 5%, 7.5%, and 10%, respectively.

      Clinical Best Practices

      • The article reports that PCE and PREVENT thresholds classify different proportions of adults as eligible for primary-prevention aspirin.
      • The article states that a PREVENT-specific threshold for aspirin discussions remains unestablished; the study’s PREVENT cutoffs were analytical comparisons, not revised recommendations.
      • The estimates apply to the study’s selected population and are subject to its survey-based bleeding-risk surrogates and self-reported ASCVD history and aspirin use.

      Related Resources & Content

      Original Source(s)

      Related Content